stockrowBenitec Biopharma Limited
BNTC Healthcare Biotechnology
Benitec Biopharma Limited’s revenue for fiscal 2023 (year ended June 2023) was $75,000.00, up 2.74% from fiscal 2022.
- EPS
- −11.3%
- Free cash flow
- +38.9%
- Total debt
- −46.3%
Quarter to June 2026, against a year earlier
Follow BNTC
Alert me
Benitec Biopharma Limited (BNTC) EV/Sales
As of 6 November 2026, Benitec Biopharma Limited (BNTC) trades at a EV/Sales of 3,500×. Over the past ten years it has ranged from −261× (December 2023) to 7,890× (October 2025); the current reading is higher than 85% of that period. That is above the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2023 | 45.4× | — |
| FY2023 | −60.9× | — |
| FY2022 | 79.5× | (78.56%) |
| FY2022 | 371× | — |
| FY2021 | −25.2× | — |
| FY2021 | 9.4× | — |
| FY2020 | −93.6× | — |
| FY2020 | −1.4× | — |
| FY2019 | 0.0× | — |
| FY2019 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2023 | 45.4× | — |
| Mar 2023 | −2.9× | — |
| Dec 2022 | −60.9× | — |
| Jun 2022 | 79.5× | (45.47%) |
| 12 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| SCTX Scribe Therapeutics Inc. compare | n/m |
| KYTX Kyverna Therapeutics, Inc. compare | n/m |
| EIKN Eikon Therapeutics, Inc. compare | n/m |
| GALT Galectin Therapeutics Inc. compare | n/m |
| ALEC Alector, Inc. compare | 0.8× |
| ENTA Enanta Pharmaceuticals, Inc. compare | 2.0× |
| AGEN Agenus Inc. compare | 3.2× |
| XFOR X4 Pharmaceuticals, Inc. compare | 17.0× |
| BNTC Benitec Biopharma Limited | 3,500× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)